Skip to content

Study · Not a test of the peptide alone · 2003

1 result

Anti-inflammatory effects in the skin of thymosin-beta4 splice-variants.

Girardi M, Sherling MA, Filler RB, Shires J, Theodoridis E, Hayday AC, Tigelaar RE

Immunology1 May 2003Cited by 38 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Activity measurement

    In mouse skin inflammation models, the lymph-specific splice variant LTbeta4 had broader and most often stronger anti-inflammatory activity than the ubiquitous form UTbeta4.

    In plain wordsIn mice, a lymph-specific form of thymosin beta‑4 reduced skin inflammation more broadly and more strongly than the ubiquitous form.

    Outcome
    Not applicableAnti-inflammatory activity of LTbeta4 versus UTbeta4 in skin
    Study

    mousen: not reported in source

    Skin inflammation models: footpad carrageenan, irritant contact dermatitis, allergic contact dermatitis
    Comparator
    UTbeta4
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    These studies clearly showed that the anti-inflammatory activities of LTbeta4 were broader and most often stronger than those of UTbeta4.
    1 context sentence
    Summary · context
    To compare the anti-inflammatory properties of LTbeta4 and UTbeta4 in the skin in vivo, the biological activities of synthesized polypeptides were assessed using three different strategies: neutrophil infiltration by footpad lambda-carrageenan injection; irritant contact dermatitis to 12-O-tetradeca…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.